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ABSTRACT The quality of care can be improved by the development and implementation of evidence-
based treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease
(COPD) exist in Europe and relevant differences may exist among them.
This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years.
Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis,
risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were
available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal,
Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities
in treatment selection and support for use of long-acting bronchodilators, were similar across treatment
guidelines. There were differences in measures used for stratification of disease severity, consideration of
patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other
medications (e.g. theophylline and mucolytics) in addition to bronchodilators.
There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of long-
acting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe
and Russia. However, there are differences in the definitions of patient subgroups and other recommended
treatments.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a critically important international health problem. The
prevalence of COPD in Europe has been estimated to range between 4% and 10% [1, 2], and between 1994
and 2010, 2348184 deaths were attributed to COPD in the European Union [3]. It has been repeatedly
suggested that management of the very large number of patients with COPD can be improved by the
development and implementation of evidence-based treatment guidelines [4, 5].
There are many definitions of clinical guidelines, which may be characterised as: “…systematically
developed statements designed to help practitioners and patients decide on appropriate healthcare for
specific clinical conditions and/or circumstances” [6]. It has been noted that the difference between a
guideline and a statement is based on methodological requirements. For example, an official scientific
statement from the European Respiratory Society (ERS) requires a comprehensive scientific review of the
literature by an ERS task force, while a clinical practice guideline also includes systematic reviews, grading
of the quality of the evidence and grading of recommendation strength [7, 8].
In Europe multiple national guidelines for the treatment of COPD exist. It appears important to
understand similarities and differences among them and how they might influence patient management in
order to improve future guidelines development at both global and national levels. The aim of this review
is to carry out a detailed comparison of these guidelines, but not to review them critically.
Methods
National guidelines for treatment of COPD published in the past 7 years in the European Union and Russia
were identified and retrieved. This included guidelines from the Czech Republic [9], England and Wales
[10], Finland [11, 12], France [13], Germany [14], Italy [15], Poland [16], Portugal [17], Russia [18], Spain
[19, 20] and Sweden [21]. Each guideline was reviewed in detail and information about the most important
aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised
process. These included the following: criteria for establishment of a diagnosis of COPD; evaluations used
for determination of disease severity and future risk (primarily for exacerbations); definition of patient
subgroups employed to guide decisions with respect to initial treatment; treatment goals for patients with
stable COPD; choices for initial disease management in different patient subgroups; the role of combination
therapy with long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), including
fixed combinations of these agents; criteria for the use of inhaled corticosteroids (ICS); additional
treatments that might be employed for treatment of patients with stable COPD; and the influence of
comorbidities on COPD treatment decisions. Extracted information was tabulated for comparison.
Results
Diagnostic criteria
The criterion defining airflow obstruction used for the diagnosis of COPD in most national guidelines was
a post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio <70%
(England and Wales, France, Germany, Finland, Portugal and Russia). The guidelines from the Czech
Republic, Italy, Poland and Sweden all specified a post-bronchodilator FEV1/FVC ratio less than the lower
limit of normal (LLN) (i.e. below the 5th percentile for age, sex and height). The Spanish guidelines use
the fixed ratio as the criterion for diagnosis, except in patients aged <50 years and >70 years, for whom the
LLN is recommended.
Stratification of disease severity and prediction of future risk
Guidelines from the Czech Republic, England and Wales, France, Germany, Poland, Portugal, Russia and
Sweden stratified patients on the basis of the degree of airflow limitation into the four stages set forth in
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, as follows. Stage 1 (mild):
FEV1 ⩾80% predicted; stage 2 (moderate): FEV1 50–79% pred; stage 3 (severe): FEV1 30–49% pred; and
stage 4 (very severe): FEV1 <30% pred [22]. The Italian guidelines combined stage 3 and stage 4 in a single
“severe” category. The guidelines from Finland identified patients as low risk (FEV1 ⩾50% pred) and high
risk (FEV1 <50% pred) and provided a separate tool for assessing severity of airflow obstruction according
to GOLD strategy as well as assessing severity of full clinical presentation. The Spanish guidelines did not
consider FEV1 alone to categorise patients’ severity, but rather used the BODE (body mass index, airflow
obstruction, dyspnoea and exercise capacity) index [23] or BODEx (replaces exercise with exacerbations)
[24] for patient stratification. With the BODE index, 0–2 is considered mild COPD, 3–4 moderate, 5–6
severe and ⩾7 very severe (table 1).
Most guidelines considered symptom severity. Those from the Czech Republic divided patients into groups
with COPD assessment test (CAT) scores <10 and ⩾10 or modified Medical Research Council (mMRC)
dyspnoea scores of 0 or ⩾1; those from Finland divided groups into those with CAT <10 and ⩾10; those
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from Poland and Portugal considered CAT and mMRC scores; those from Russia and Sweden employed
CAT, mMRC and clinical COPD questionnaire (CCQ) scores; those from Spain employed CAT scores as a
measure of disease control at each level of severity [25]; and those from France divided patients on the
basis of episodic or daily symptoms and mMRC scores to establish the indications for short- versus
long-acting bronchodilators. The guidelines from England and Wales recommend evaluation using the
mMRC dyspnoea scale, presence of systemic symptoms, body mass index, health status (measured by
CAT), exercise capacity (6-min walking distance) and oxygenation as expressed arterial oxygen tension for
a more detailed determination of disease severity if necessary (table 1).
Recognition of patient subtypes or phenotypes
There was variability across national guidelines with respect to the identification of patient subtypes, and
this may be related, at least in part, to the times at which different guidelines were published. For example,
the oldest guidelines included in the analysis were from Germany and do not consider phenotypes, while
more recent guidelines generally recognise multiple patient phenotypes. The classic phenotypes of chronic
bronchitis and emphysema were recognised in recommendations from the Czech Republic, England and
Wales, Poland, Russia, Spain and Sweden (bronchitic only) (table 2).
The asthma–COPD overlap syndrome (ACOS) phenotype was recognised in recommendations from the
Czech Republic, Finland, Russia, Spain and Sweden. As noted earlier, this phenotype was not specifically
TABLE 1 Stratification of chronic obstructive pulmonary disease (COPD) severity/future risk
Severity of airflow limitation Symptom severity Exacerbation risk
Czech Republic GOLD stages 1, 2, 3 and 4 mMRC or CAT Low risk: 0–1 exacerbations
High risk: ⩾2 exacerbations
England and Wales# FEV1/FVC <70% pred and
Mild: FEV1 ⩾80% pred; moderate: FEV1
50–79% pred; severe:
FEV1 30–49% pred; very severe:
FEV1 <30% pred
Presence of systemic symptoms
BMI
Health status: measure not
specified (CAT in NICE
quality standard)
Exercise capacity
(e.g. 6-min walking distance)
PaO2
Not specified
Finland Low risk: FEV1 ⩾50% pred
High risk: FEV1 <50% pred¶
CAT score <10 or ⩾10 High risk: ⩾2 exacerbations
or one leading to hospitalisation
in the past year
France GOLD stages 1, 2, 3 and 4 mMRC
Episodic versus daily occurrence
of dyspnoea on exercise
History of exacerbations (⩾2)
Germany GOLD stages 1, 2, 3 and 4 Not graded or used for
assessment
Not graded or used
for assessment
Italy Mild: FEV1 ⩾80% pred; moderate:
FEV1 <80% pred and ⩾50% pred;
severe: FEV1 <50% pred
None stated None stated
Poland Mild: FEV1 ⩾80% pred; moderate:
FEV1 <80% pred and ⩾50% pred;
severe: FEV1 ⩾30% pred and <50% pred;
very severe: FEV1 <30% pred
mMRC or CAT High risk: FEV1 <50% pred, or ⩾2
exacerbations treated with antibiotics
or 1 hospitalisation due to exacerbation
within past 12 months
Portugal GOLD stages 1, 2, 3 and 4
Overall: GOLD A, B, C and D
classification used
mMRC or CAT Low risk: 0–1 moderate exacerbations
High risk: ⩾2 moderate or ⩾1 severe
exacerbation
Russia Mild: FEV1 ⩾80% pred; moderate:
FEV1 <80% pred and ⩾50% pred;
severe: FEV1 ⩾30% pred and <50% pred;
very severe: FEV1 <30% pred
mMRC, CAT or CCQ High risk: according to GOLD 2011
classification (high risk ⩾2
exacerbations or ⩾1
hospitalisation per year)
Spain GOLD stages 1, 2, 3 and 4 CAT Low risk: 0–1 exacerbations
High risk: ⩾2 exacerbations
Sweden FEV1 CAT, CCQ or mMRC Number per year
GOLD: Global Initiative for Chronic Obstructive Lung Disease; mMRC: modified Medical Research Council; CAT: COPD assessment test;
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BMI: body mass index; NICE: National Institute for Health and Care Excellence;
PaO2: arterial oxygen tension; CCQ: clinical COPD questionnaire. #: the guidelines for England and Wales also assess PaO2; ¶: provides a separate
tool for assessing severity of obstruction according to GOLD strategy as well as assessing the severity of full clinical presentation.
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recognised in recommendations from Germany and this was also the case for France and Italy. In the
Czech Republic guidelines, the major criteria for a diagnosis of ACOS in a patient that also meets the
criteria for a diagnosis of COPD were the degree of reversibility in bronchodilator testing (FEV1 >15%
pred and >400 mL), exhaled nitric oxide fraction (FeNO) ⩾45–50 ppb and/or elevated sputum eosinophils
⩾3%, and history of asthma. In the Finnish guidelines, major diagnostic criteria for ACOS included a
significant bronchodilator response (FEV1 >15% pred and >400 mL), sputum eosinophilia or elevated
FeNO (>50 ppb), and previous symptoms compatible with asthma starting when the patient was <40 years
of age in addition to meeting the criteria for a diagnosis of COPD. The Spanish guidelines include a
TABLE 2 Patient phenotypes/groups to guide treatment decisions
Use of phenotypes/
groups
Type 1 Type 2 Type 3 Type 4
Czech Republic# Yes Bronchitic: productive





cough and signs of
emphysema
Frequent exacerbator:









Frequent exacerbator Smoking, respiratory
failure, cor
pulmonale, abnormal
BMI and anxiety and
depression






















Italy Yes Airflow limitation Emphysema
Poland Yes Chronic bronchitis:
dominant symptoms












Portugal Yes Frequent exacerbator:
⩾2 exacerbations per
year or ⩾1 exacerbation
requiring hospitalisation
















































of both COPD and
asthma
COPD: chronic obstructive pulmonary disease; ACOS: asthma–COPD overlap syndrome; BMI: body mass index; FEV1: forced expiratory volume
in 1 s. #: recommendations also include COPD + bronchiectasis and pulmonary cachexia phenotypes.
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positive bronchodilator test (increase in FEV1 >15% and >400 mL), eosinophilia in sputum and a personal
history of asthma as major criteria for ACOS. Criteria for a diagnosis of ACOS are not stated in the Polish
and Russian guidelines.
The frequent exacerbator phenotype was recognised in recommendations from the Czech Republic,
England and Wales, Finland, Poland, Portugal, Russia, Spain and Sweden. Those from the Czech Republic
defined frequent exacerbators as those with a history of two or more exacerbations in the past year. The
guidelines from Finland, Russia, Portugal and Spain defined frequent exacerbators as those who had two or
more exacerbations or one or more severe exacerbation leading to hospitalisation in the previous year. The
guidelines from Poland used these criteria and also included those with FEV1 <50% pred as being likely to
have exacerbations. Guidelines from Sweden also considered the number of exacerbations in the previous
year for patient stratification. French guidelines identified patients with repeated exacerbations, mostly for
the purpose of defining some treatment indications (indication for ICS + LABA combination, see later).
Treatment goals
Recommendations from the majority of countries identified decreasing severity of current symptoms,
reducing future risk for exacerbations, slowing disease progression and/or lowering mortality as significant
treatment goals. The guidelines from the Czech Republic, Finland, France, Poland, Portugal and Sweden
all cited reducing symptoms, averting the natural progression of the disease, improving quality of life,
enhancing physical activity, preventing complications and adverse consequences and increasing life
expectancy as treatment goals. Those from Germany and Spain included improvement of symptoms,
exercise capacity, quality of life and reduction of exacerbation frequency. The guidelines from Russia had
short-term goals of symptom relief and improvement of exercise tolerance and quality of life and
long-term goals of preventing disease progression and exacerbations and decreasing mortality. While
overall treatment goals were not explicitly stated in the Italian guidelines, they did note that the main goal
of pharmacotherapy for patients with COPD was bronchodilation.
Treatment selection
Recommended initial pharmacotherapy was generally a short-acting β2-agonist (SABA) or short-acting
antimuscarinic agent (SAMA) in patients with mild disease. In more symptomatic patients, a LABA or
LAMA was the preferred treatment. No guideline provided precise criteria to choose between these
options. The association of LABA + LAMA was an alternative choice in the Czech Republic, England and
Wales, Finland, Italy, Poland, Russia, Spain and Sweden; in France, it was to be considered when a single
agent did not provide satisfactory effectiveness; and it was a major choice for GOLD group C patients in
Sweden. Recommendations from Poland, Portugal, Russia and Sweden stratified initial treatment on the
basis of the GOLD A–D classification scheme [22]; and both France and Germany based treatment
selection mainly on the severity of airflow obstruction according to GOLD spirometric severity stage [22]
(table 3). The French guidelines also considered the burden of dyspnoea for choosing between short-acting
and long-acting bronchodilators and exacerbations in deciding whether to employ ICS + LABA
combinations in patients with severe airflow obstruction.
Several guidelines tailored preferred treatment recommendations on the basis of patient phenotype.
Guidelines from the Czech Republic indicated that bronchitic patients might require a phosphodiesterase
(PDE) type 4 inhibitor, a mucoactive agent, and/or macrolide added to bronchodilator treatment and that
patients with emphysema might also receive theophylline. Recommendations for patients with ACOS
included ICS + LABA or ICS + LABA + LAMA (Czech Republic, Finland and Spain) and the possibility
of adding a leukotriene response modifier (Czech Republic, but not supported by any clinical trial results
in patients with ACOS). Recommendations for preferred therapy for frequent exacerbators included
standard treatment and PDE4 inhibitor, ICS + LABA, mucoactive drugs and antibiotics (Czech Republic);
ICS + LABA (France); ICS + LABA or LAMA (Finland, Spain and Poland); addition of ICS to a
long-acting bronchodilator (Germany); and LAMA, ICS + LABA, LABA + LAMA or ICS + LABA +
LAMA (England and Wales).
Recommendations for treatment with LABA + LAMA varied across national guidelines (table 4).
Combination of LABA + LAMA was listed as an alternative choice in the guidelines from Finland, France,
Poland, Portugal and Spain. In Germany and Russia, LABA + LAMA combination was a first choice for
treatment of specific patient subgroups, whereas in the Czech Republic combination therapy was an option
for all patients. In England and Wales, a LABA + LAMA combination was recommended in patients
where LABA + ICS were indicated, but ICS was declined or could not be tolerated. It may also be
considered in patients with persistent breathlessness despite treatment with LAMA, LABA or LABA + ICS.
None of the guidelines provided specific recommendations regarding the use of fixed-dose LABA +
LAMA combinations.
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In the majority of guidelines, the criteria for the proper use of ICS were roughly similar. ICS was
recommended in combination with bronchodilators in patients with FEV1 <50% (or <60%) pred, at high
risk for exacerbations and/or with a history of two or more exacerbations in the previous year, as well as in
those with ACOS. In patients without ACOS, ICS use was generally restricted to patients not effectively
managed with bronchodilators alone, and usually to those with two or more exacerbations per year,
eventually further restricted to patients with severe airflow obstruction (France) (table 4).
Additional treatments were considered in all recommendations (table 5). Theophylline was recommended
with reservations by all countries except Italy. Roflumilast was recommended in patients with severe
COPD with characteristics of chronic bronchitis and a history of exacerbations in most countries.
However, this agent is not available or not reimbursed in England and Wales, France, Poland and
Portugal. It is currently reimbursed in Germany, but was not available at the time the guidelines were
TABLE 3 Preferred first treatment choice
Patient type 1 Patient type 2 Patient type 3 Patient type 4
Czech Republic# Bronchitic: standard treatment
+ one or more options: PDE4
inhibitor if exacerbator,
mucoactive drugs or antibiotics
Emphysematous: standard
treatment + one or more
options: theophylline, BVR,
LVRS, bullectomy or α1-AT
Frequent exacerbator:
standard treatment + one
or more options: PDE4
inhibitor, ICS + LABA,
mucoactive drugs or
antibiotics
ACOS: standard treatment +
one or more options:
ICS + LABA, ICS + LABA +
LAMA or anti-leukotrienes
England and Wales Breathlessness and exercise
limitation: SABA or SAMA
Exacerbations or
breathlessness and FEV1
⩾50% pred: LABA or LAMA
Exacerbations or
breathlessness and
FEV1 <50%: LAMA or
ICS + LABA
Persistent exacerbations or
breathlessness: ICS + LABA
or LABA + LAMA if ICS
declined or not tolerated or
LAMA + ICS + LABA
Finland Low risk for exacerbations:
SABA or SAMA





ACOS: at least ICS + LABA
or ICS + LABA + LAMA
France GOLD 1: SABA or SAMA (or
both)
GOLD 2: LABA or LAMA
(both if dyspnoea persists
during usual exercise)
GOLD 3: ICS + LABA if
repeated exacerbations or
LABA + LAMA
GOLD 4: triple therapy
(ICS + LABA + LAMA) if
previous step is not
sufficient
Germany GOLD 1: avoidance of risk
factors; vaccination(s); and
SABA
GOLD 2: add LABA(s) and
rehabilitation
GOLD 3: add ICS in
patients with frequent
exacerbations
GOLD 4: add LTOT; possible
indication for surgery
Italy Symptomatic with confirmed
diagnosis of COPD, mMRC
stage ⩾1 and prebronchodilator






<80% pred: consider LABA




add ICS in frequent
exacerbators
Poland CAT <10, FEV1 ⩾50% pred, low
exacerbation: SABA or SAMA
CAT ⩾10, FEV1 ⩾50% pred,
low exacerbation: LABA or
LAMA
CAT <10, FEV1 <50% pred,
high exacerbation: LAMA
or ICS + LABA
CAT ⩾10, FEV1 <50% pred,
high exacerbation: LAMA
and/or ICS + LABA
Portugal GOLD A: SABA or SAMA GOLD B: LABA or LAMA GOLD C: LAMA or
ICS + LABA
GOLD D: LAMA and/or
ICS + LABA
Russia GOLD A: SABA or SAMA GOLD B: LABA or LAMA GOLD C: LAMA or
ICS + LABA
GOLD D: ICS + LABA,
LAMA, ICS + LABA
+ LAMA
Spain Nonexacerbator: LAMA or
LABA






Sweden GOLD A: SABA or SAMA GOLD B: LAMA GOLD C: ICS + LAMA or
ICS + LABA + LAMA
GOLD D:
LAMA + LABA + ICS
PDE: phosphodiesterase; BVR: bronchoscopic volume reduction; LVRS: lung volume reduction surgery; α1-AT: α1-antitrypsin; ICS: inhaled
corticosteroid; LABA: long-acting β2-agonist; ACOS: asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome; LAMA: long-acting
muscarinic antagonist; SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist; FEV1: forced expiratory volume in 1 s; GOLD:
Global Initiative for Chronic Obstructive Lung Disease; LTOT: long-term oxygen therapy; mMRC: modified Medical Research Council; LABD:
long-acting bronchodilator; CAT: COPD assessment test. #: recommendations for standard treatments include inhaled bronchodilators (LABA,
LAMA, ultra-LABA and ultra-LAMA), pulmonary rehabilitation, vaccination, education, long-acting muscarinic antagonist, inhalation training,
dietary changes, comorbidity treatment and risk elimination. Patients with COPD and bronchiectasis receive a PDE4 inhibitor, mucoactive drugs,
antibiotics and physiotherapy; and those with pulmonary cachexia receive rehabilitation and nutritional support.
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written. Macrolides could be used as alternative treatment for stable disease in patients still experiencing
exacerbations despite optimal treatment in the Czech Republic, Finland, Russia and Spain. They were not
recommended for stable disease in Poland, and other countries did not provide recommendations.
N-acetylcysteine/oral carbocisteine were both recommended in the Czech Republic, England and Wales
(with caveats), Poland, Russia and Spain, but not recommended in Finland, France and Portugal.
Impact of comorbidities on COPD treatment decisions
Recommendations from most countries (England and Wales, France, Germany, Italy, Poland, Portugal,
Spain and Sweden) did not suggest alterations in COPD treatment in patients with common comorbidities
(online supplementary table S1). However, they did indicate that comorbidities should be evaluated and
appropriately managed. Recommendations from Finland and Russia suggested caution/careful
consideration regarding use of ICS in patients with or at risk of osteoporosis, diabetes and pneumonia; and
also for high-dose β2-agonists in patients with cardiovascular disease.
Discussion
The European and Russian guidelines for the treatment of COPD have numerous differences when
considered in detail, but they also have many general similarities with respect to both diagnosis and
management of patients with this disease. There are many potential reasons for differences between
guidelines, which might include differences in national healthcare systems, differences in opinions
regarding cost-effectiveness of drugs, reimbursement issues and availability of medications. However, it is
reasonable to suggest that one of the most important reason for differences among guidelines is the
TABLE 4 Use of long-acting β2-agonist (LABA) + long-acting muscarinic antagonist (LAMA) combinations and inhaled
corticosteroids (ICS)
LABA + LAMA ICS
Czech Republic Option for all patients; depends on severity Patient with ACOS or frequent exacerbator
England and Wales Consider in patients indicated for ICS + LABA if ICS
refused or cannot be tolerated Consider in patients with
persistent breathlessness despite treatment with LAMA,
LABA or ICS + LABA
Patients who remain breathless or have exacerbations
despite using short-acting bronchodilators and FEV1 <50%
pred and in patients with FEV1 ⩾50% pred who remain
breathless or have exacerbations despite maintenance
therapy with a LABA; increased risk of pneumonia is
mentioned
Finland Alternative choice Patient belongs to high exacerbation risk group (frequent
exacerbations despite the use of appropriate bronchodilator
therapy, FEV1 <50–70% pred) or presents with ACOS;
increased risk of pneumonia is mentioned
France GOLD stage 2 patients if there is dyspnoea during usual
activities despite single long-acting bronchodilator
GOLD stages 3 and 4
Used only as part of fixed-dose combinations; FEV1 <50%
pred (<60% pred for salmeterol/fluticasone) and repeated
exacerbations (⩾2 per year) and symptoms despite regular
treatment with bronchodilator(s) (LABA and/or LAMA)
Germany GOLD stage 2 and higher (possibly triple therapy and
additional treatments in GOLD stages 3 and 4)
FEV1 <50% pred and ⩾1 exacerbation treated with systemic
steroids and/or antibiotics in the past year
Italy A second long-acting bronchodilator with a
complementary mechanism of action may be added if the
patient and/or physician are not satisfied with the
response to single-agent therapy
In symptomatic patients, with prebronchodilator FEV1 <60%
pred and ⩾2 exacerbations per year; ICS may be added to
LABA
Poland Alternative choice ⩾2 COPD exacerbations treated with antibiotics/oral
steroids or ⩾1 hospitalisation due to COPD exacerbation
within past 12 months, or FEV1 <50% pred
Portugal Alternative choice ICS are recommended in GOLD classes C and D; no specific
criteria are stated for use in these classes, but frequent
exacerbations should prompt augmentation of therapy
Russia First choice in GOLD D patients
Alternative choice in GOLD B and C patients
Frequent exacerbations, sputum eosinophilia or systemic
inflammation; increased risk of pneumonia is mentioned
Spain Alternative choice (nonexacerbator) ACOS, exacerbator phenotype despite optimal
bronchodilation; increased risk of pneumonia is mentioned
Sweden Alternative choice in GOLD B patients
First choice in GOLD C and D patients
Repeated exacerbations or FEV1 <50–60% pred
ACOS: asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome; FEV1: forced expiratory volume in 1 s; GOLD: Global Initiative
for Chronic Obstructive Lung Disease.
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evidence available at the times when they were developed. The publication dates for the guidelines
reviewed ranged from 2007 for Germany to 2015 for Finland.
The guidelines generally encourage the consideration of a diagnosis of COPD and evaluation with
spirometry in symptomatic patients with risk factors, most notably tobacco smoking [9, 10, 12, 15].
However, review of these recommendations prompts the suggestion that simplification of diagnostic
criteria, particularly for primary care physicians, could significantly enhance patient identification and
initiation of care. This is an important issue since multiple studies from Europe have indicated that COPD
is greatly underdiagnosed [1, 26–31].
There was one notable difference among countries with respect to diagnosis of COPD. The guidelines
from England and Wales, Finland, France, Germany, Portugal and Russia all used FEV1/FVC <70% as the
spirometric criterion for a diagnosis of persistent airway obstruction and COPD, while the Czech Republic,
Italy, Poland and Sweden used FEV1/FVC <LLN. It has been considered that the use of the fixed ratio
FEV1/FVC <70% yields false negative results in individuals aged <50 years and false positive results in
those aged >70 years [32–34]. However, a fixed ratio appears to be much simpler to implement, especially
in non-specialised settings. For this reason, the Spanish guidelines suggest using the LLN criterion for
individuals in those age groups [19, 35].
All guidelines used the same cut-offs for FEV1 in defining the severity of airflow obstruction. Most of the
guidelines reviewed (exceptions were Germany and Italy) used a combination of measures for the
determination of disease severity, impact and establishment of patient prognosis. This is consistent with
results of numerous studies indicating that FEV1 alone does not provide the best prediction of treatment
outcomes for patients with COPD [23, 36–38]. Consideration of guidelines and the clinical literature
supports the view that assessment of disease severity and establishment of prognosis should be based on
multiple factors, including exacerbation history, symptoms (including activity limitation) and pulmonary
TABLE 5 Additional treatments for stable chronic obstructive pulmonary disease (COPD)
Theophylline Roflumilast Macrolide N-acetylcysteine Oral carbocisteine
















England and Wales REC: after inhaled
treatments
NR NR REC NR
Finland REC: possibly in
patients with low
exacerbation risk















Not reimbursed NR NO NO
Germany REC: third choice Not available Studies not
available
REC: only for viscous
secretions
NR









REC: not reimbursed NO REC REC
Portugal REC: only if better
options cannot be
used
Not available NR NR NR
Russia REC REC REC REC REC
Spain REC: third-line REC: second-line REC: third-line REC: second-line REC: second-line
Sweden NO: but may be used REC NR NO NR
REC: recommended; NR: no recommendation; FEV1: forced expiratory volume in 1 s; NO: not recommended.
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function [23, 24, 39]. This is reflected in the Spanish guidelines which employ BODE [23] or BODEx [24]
for patient stratification. The utility of these two metrics for patient stratification and outcome prediction
is supported by results from multiple studies. The BODE index is also mentioned for severity assessment
in the French guidelines. It has been shown to be a significant predictor of exacerbations, hospitalisation,
quality of life and respiratory and all-cause mortality in patients with COPD [23, 40–43]. The Spanish
guidelines recommend the use of the BODEx, which replaces exercise capacity with exacerbation history,
as an alternative to the BODE index in patients with GOLD stage I or II disease [19, 35]. This simplifies
patient evaluation with no decrement in predictive value for mortality [24]. The extensive use of these
composite measures and validation of their predictive value for multiple end-points supports their routine
use in the initial assessment of patients with COPD.
The guidelines reviewed were in agreement regarding the existence of distinct subgroups of COPD
patients, and the ACOS and frequent exacerbator “phenotypes” were generally accepted [9, 10, 12, 16–19,
21, 35]. Results from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE) study and other evaluations have suggested that the frequent exacerbator phenotype is relatively
stable over a 3-year follow-up [44]. However, consideration of guidelines also indicates that it is not clear
whether some COPD phenotypes are stable or can change with therapy and thus might be best considered
as treatable characteristics rather than definitive traits in specific patients.
For most guidelines, patients with ACOS have disease characterised by increased reversibility of airflow
obstruction, eosinophilic bronchial and systemic inflammation and increased responsivity to ICS,
compared with other COPD patients. They also have more frequent exacerbations and more wheezing and
dyspnoea [45–48]. While clear criteria for the diagnosis of ACOS have been set forth [9, 12, 19, 35], they
have not been prospectively validated. In addition, a question that remains unanswered is whether ACOS
should be considered as a distinct entity or rather as concomitant diseases that overlap [49].
There also has been considerable discussion regarding whether subgroups of patients with different clinical
characteristics should be considered as distinct phenotypes and whether or not this term is useful for patient
description, especially as drivers for treatment decisions [20, 35, 50]. Consideration of patient subgroups with
COPD is further complicated by the fact that many have multiple comorbid conditions, including
cardiovascular disease [51], lung cancer [52], frequent respiratory tract infections [53], osteoporosis [54],
diabetes [55], metabolic syndrome [56] and psychiatric disease [57]. The guideline for England and Wales is
innovative in advocating a simultaneous multidimensional assessment and management approach that
includes comorbidities/systemic effects of COPD. There is general recognition that comorbidities should be
integrated into guidelines developed for the management of patients with COPD [58].
There was general good agreement between guidelines with respect to the selection of preferred therapy in
patients with different disease severities. However, the selection of “initial” therapy by a pulmonologist is
complicated by the fact that most COPD patients are initially managed by general practitioners prior to
referral and there is little evidence-based guidance for treatment selection in post-referral patients who
have already been treated. Most patients with COPD are symptomatic by the time they are referred to a
pulmonologist and should therefore receive treatment with long-acting bronchodilators. At present, we do
not have evidence that provides a basis for stepping up or down treatment in patients with COPD and
research addressing these questions is greatly needed.
More information is also needed regarding the benefits of a LABA + LAMA combination versus either
agent alone. Results from several studies have made clear that combination of LABA + LAMA provides
improvements in pulmonary function significantly greater than those achieved with monotherapy [59–61].
There is a growing body of evidence supporting the benefits of LABA + LAMA therapy versus single
agents for reducing symptoms and decreasing the frequency of exacerbations [59–63], but more
information is awaited about the comparison of LABA + LAMA versus LABA + ICS for the prevention of
exacerbations in high-risk patients.
Inhaled corticosteroids are effective in patients with ACOS [64, 65], and they have a significant benefit in
decreasing exacerbations and reducing symptom severity in other groups of COPD patients [66, 67].
However, there are some risks of significant side-effects (e.g. pneumonia) associated with ICS use [68–70],
which must be considered in any treatment recommendations regarding these agents. Selection of candidates
for ICS treatment would be facilitated by the availability of biomarkers predicting effectiveness (e.g. elevated
sputum [64, 71] or blood eosinophils [72]), but more research is needed in this “hot topic” area.
Guidelines for diagnosis, assessment and management of patients with COPD generally lack a formal
definition of disease control that takes into account COPD severity at the initiation of treatment and
which can be used to evaluate efficacy of therapy. It is reasonable to suggest that such a definition should
be included in treatment recommendations. SOLER-CATALUÑA et al. [25] have set forth criteria for control of
disease that consider both impact of disease, as measured by instruments such as the CAT or CCQ, and
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stability, as reflected by an absence of exacerbations and no deterioration in questionnaire results. Using
this approach, treatment is intensified or decreased, as appropriate to maintain stability and low impact
[25]. Addition of criteria for longitudinal patient assessment and adjustment of therapy may be a useful
addition to treatment guidelines.
Guidelines for the treatment of any disease have little meaning unless they are integrated into clinical
practice [73]. Results from multiple surveys indicate that actual treatment for many patients with COPD
may not be consistent with available treatment recommendations. A recent analysis of prescribing patterns
in 24957 patients revealed that COPD was not treated according to GOLD and National Institute for
Health and Care Excellence recommendations in the UK primary-care setting, with significant proportions
of patients receiving no treatment despite experiencing symptoms [26]. Interestingly, most COPD patients
received ICS irrespective of severity of airflow limitation, asthma diagnosis and exacerbation history,
whereas many patients on treatment were still symptomatic [26]. An observational study which included
information from 4094 patients with COPD treated in Italy also indicated poor adherence to GOLD
treatment recommendations, with 62.1% of the patients receiving pharmacotherapy that was inappropriate
for their disease severity [74]. An evaluation of 1355 patients with COPD in the Czech Republic indicated
that 32.8% of cases were misclassified according to GOLD categories. Furthermore, 15.4% of patients
received ICS unnecessarily, whereas in 15.8% of cases ICS were erroneously omitted [75]. In a French
cohort study, ICS were prescribed outside their indications in ∼75% of patients if the “old” GOLD
guidelines were taken as the reference, and in one-third when considering the new GOLD document
[76, 77]. This study also underlined the high proportion of patients on triple therapy, which is supported
by only a few studies and contradicted by others [78–80].
Physicians’ reports of their own practice patterns also indicate variability regarding adherence to and
knowledge of treatment guidelines. A survey of 1307 primary-care physicians and respiratory specialists
who regularly managed patients with COPD, emphysema or chronic bronchitis indicated good awareness
of guidelines and frequent use of recommended diagnostic practices. However, there were significant
deviations from guideline-recommended treatment. Physicians reported using spirometry routinely
(primary-care physicians 82% and respiratory specialists 100%) to diagnose COPD and frequently included
validated patient-reported outcome measures (primary-care physicians 67% and respiratory specialists
81%). The percentages of primary-care physicians and respiratory specialists providing first- or
second-choice treatment consistent with the GOLD recommendations for a type B patient were 38% and
67%, respectively. Those for type C patients were 40% and 38%, respectively and those for type D patients
were 57% and 58%, respectively [81]. In contrast, a survey of 590 respiratory specialists in Germany
indicated good knowledge of approaches to COPD diagnosis and classification as well as treatment
selection for patients with moderate or severe disease [82].
The limited adherence to COPD treatment guidelines may reflect issues that are not fully addressed due to
insufficient information available from controlled clinical trials [8] and possibly also by the view that they
reflect greater clinical efficacy in controlled trials than treatment effectiveness achievable in broad patient
populations being managed in routine care in real-world settings [83].
Providing concise and succinct treatment recommendations relevant for both general and specialist
physicians may improve their employment for guidance of patient management. The ERS has noted the
importance of trustworthy documents to guide patient management and have established a guidelines
working group to facilitate development, dissemination and implementation of guidelines [7]. However, it
is also recognised that the methodology involved in the development of such guidelines requires
specialised knowledge (e.g. application of the GRADE (Grading of Recommendations, Assessment,
Development and Evaluation) criteria to information providing the basis for the guidelines) and is time
consuming and very costly [84]. A potentially efficient approach for the development of COPD treatment
guidelines may be initial formulation at the international level and adaptation based on the needs and
resources in each country. This suggestion is consistent with the ERS proposal that scientific societies
should work together and establish panels to provide appropriate guidance regarding respiratory disease to
physicians and patients [7].
In conclusion, the review of guidelines indicated several areas that should be addressed and questions that
need to be answered to facilitate diagnosis and treatment of COPD (online supplementary table S2):
1) recommendations should increase suspicion of COPD among primary care physicians, who are usually
the first to encounter these patients; 2) there are distinct constellations of patient characteristics that may
be useful for establishment of prognosis and guiding treatment selection, but it is not clear whether they
should be considered as permanent phenotypes or treatable characteristics; 3) better guidance is needed
for patient treatment (stepping up or down treatment); 4) SABAs and SAMAs are suboptimal as regular
treatment for symptomatic individuals with COPD, since long-acting bronchodilators are superior;
5) more information is needed about the long-term efficacy and safety of LABA + LAMA combinations
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versus single agents and it is most important to understand their efficacy on symptoms and exacerbations;
and 6) both the potential risks and benefits should guide selection of treatments (this seems particularly
important for ICS).
It is important that guidelines be updated regularly to keep pace with that of research on the diagnosis,
characterisation and management of patients with COPD. This is becoming increasingly difficult due to
the vast effort, time and expense associated with guideline development [85] and the growing abundance
of clinically relevant literature. Maintaining good alignment of treatment recommendations and clinical
research results might be facilitated by simple and concise recommendations that would complement
detailed guidelines and could be rapidly updated as important results from clinical trials become available.
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